Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...
This quote, taken from the first leukaemia paper published in Archives of Disease in Childhood (ADC) in 1927, 1 illustrates the natural history of the most common cancer in children. Over the past 100 ...
Accelerated-phase CML is characterized by faster progression than chronic phase, with variable symptom burden including fatigue, weight loss, night sweats, bruising, and splenic enlargement.
CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...
The FDA has approved AstraZeneca’s Calquence (acalabrutinib), for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Combined with venetoclax (brand name ...
CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at ...
aDepartment of Hematology, Centre for Leading Medicine and Advanced Technologies of Institute of Health and Medicine, The First Affiliated Hospital of University of Science and Technology of China, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results